Ozoralizumab

Ozoralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC1682H2608N472O538S12
Molar mass38434.85 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.[1]

Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm.

References

  1. Kratz F, Elsadek B (July 2012). "Clinical impact of serum proteins on drug delivery". J Control Release. 161 (2): 429–45. doi:10.1016/j.jconrel.2011.11.028. PMID 22155554.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.